1 2 3 MEDICATION GUIDE ADVAIR HFA [ad′ vair[removed]Inhalation Aerosol

First Page		Document Content
Date: 2011-01-05 14:23:33 GlaxoSmithKline Asthma Chronic lower respiratory diseases Fluticasone/salmeterol Beta2-adrenergic agonist Salmeterol Inhaler Fluticasone propionate Bronchodilator Pulmonology Medicine Respiratory therapy		1 2 3 MEDICATION GUIDE ADVAIR HFA [ad′ vair[removed]Inhalation Aerosol Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 112,58 KB Share Document on Facebook

	Microsoft Word - Prosonix full abstract for DDL22_2_.doc DocID: 1rcKt - View Document
	COPD Care Map for Primary Care Patient Name: ______________________________________ DOB: ________________ Year of diagnosis:___________ Co-morbid conditions:______________________________________________________________ DocID: 1qO6l - View Document
	Virginia Asthma Action Plan School Division: ________________________________________________________________________ Name Date of Birth DocID: 1oNoo - View Document
	European Respiratory Disease Volume 8 • Issue 1 • Spring 2012 • Extract Improved Localised Lung Delivery Using DocID: 1ooQZ - View Document
	PIPELINE WATCH Seretide SPCs reach the end of the road eptember brings the expiry of supplementary protection certificates (SPCs) for GlaxoSmithKline’s Seretide (fluticasone/salmeterol) blockbuster in several European DocID: 1mZXk - View Document